MovDisordV3, Main, Exploration, bibRecord, 004B08

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients

Identifieur interne : 004B08 ( Main/Exploration ); précédent : 004B07; suivant : 004B09

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients

Auteurs : Jaime Kulisevsky [Espagne] ; Carmen García-Sánchez [Espagne] ; Marcelo L. Berthier [Espagne] ; Manel Barbanoj [Espagne] ; Berta Pascual-Sedano [Espagne] ; Alexandre Gironell [Espagne] ; Armando Estévez-González [Espagne]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-07.

RBID : ISTEX:DC8FA77A0EBB7396A67D49664331B342CAE3AE5F

Descripteurs français

Pascal (Inist)
- Antiparkinsonien, Chimiothérapie, Ergot dérivé, Etude longitudinale, Homme, Lévodopa, Parkinson maladie, Pergolide, Traitement, Trouble cognition.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Chemotherapy, Cognition, Cognition Disorders (diagnosis), Cognition Disorders (drug therapy), Cognitive disorder, Dopamine Agents (adverse effects), Dopamine Agents (therapeutic use), Drug Therapy, Combination, Ergot derivatives, Female, Follow up study, Follow-Up Studies, Frontal Lobe (drug effects), Frontal functions, Human, Humans, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Motor Skills (drug effects), Neuropsychological Tests, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pergolide, Pergolide (adverse effects), Pergolide (therapeutic use), Treatment.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agents, Levodopa, Pergolide.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Levodopa, Pergolide.
- diagnosis : Cognition Disorders, Parkinson Disease.
- drug effects : Frontal Lobe, Motor Skills.
- drug therapy : Cognition Disorders, Parkinson Disease.
- Aged, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neuropsychological Tests.

Abstract

BACKGROUND: The cognitive effects of dopaminergic treatment in Parkinson's disease (PD) are still controversial. OBJECTIVE: To evaluate, in previously untreated patients with PD, whether chronic dopaminergic stimulation produces significant cognitive changes; whether they are sustained beyond the period of a few months; and whether the cognitive status of two motor‐comparable groups is differently affected by levodopa and pergolide. DESIGN AND SUBJECTS: Parallel, randomized open study with blind neuropsychologic evaluation of 20 consecutive de novo patients with PD before and 3, 6, 12, 18, and 24 months after monotherapy with levodopa (n = 10) or pergolide (n = 10; 6‐month monotherapy; pergolide + levodopa thereafter). RESULTS: Both treatments were associated with a significant improvement in motor scores and in tests assessing learning and long‐term verbal and visual memory, visuospatial abilities, and various frontal tasks. While improvement in motor scores persisted, improvement in activities of daily living and in semantic fluency, Luria's rhythm and motor and long‐term memory tests was not sustained at the 24‐month examination. Further, performance on attentional, short‐term memory, and the Stroop tests did not change over the course of the study. CONCLUSIONS: Both treatments were associated with incomplete but long‐lasting (18 mos) improvement in many cognitive tasks which declined thereafter, suggesting that dopaminergic replacement is not enough to compensate for all cognitive deficits of PD.

Url:

https://api.istex.fr/document/DC8FA77A0EBB7396A67D49664331B342CAE3AE5F/fulltext/pdf

DOI: 10.1002/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F

Affiliations:

Espagne

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients</title>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
</author>
<author><name sortKey="Garcia Nchez, Carmen" sort="Garcia Nchez, Carmen" uniqKey="Garcia Nchez C" first="Carmen" last="García-Sánchez">Carmen García-Sánchez</name>
</author>
<author><name sortKey="Berthier, Marcelo L" sort="Berthier, Marcelo L" uniqKey="Berthier M" first="Marcelo L." last="Berthier">Marcelo L. Berthier</name>
</author>
<author><name sortKey="Barbanoj, Manel" sort="Barbanoj, Manel" uniqKey="Barbanoj M" first="Manel" last="Barbanoj">Manel Barbanoj</name>
</author>
<author><name sortKey="Pascual Edano, Berta" sort="Pascual Edano, Berta" uniqKey="Pascual Edano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name>
</author>
<author><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name>
</author>
<author><name sortKey="Estevez Onzalez, Armando" sort="Estevez Onzalez, Armando" uniqKey="Estevez Onzalez A" first="Armando" last="Estévez-González">Armando Estévez-González</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:DC8FA77A0EBB7396A67D49664331B342CAE3AE5F</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F</idno>
<idno type="url">https://api.istex.fr/document/DC8FA77A0EBB7396A67D49664331B342CAE3AE5F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000429</idno>
<idno type="wicri:Area/Istex/Curation">000429</idno>
<idno type="wicri:Area/Istex/Checkpoint">003309</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Kulisevsky J:chronic:effects:of</idno>
<idno type="wicri:Area/Main/Merge">007406</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0395325</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B85</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000136</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002C37</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Kulisevsky J:chronic:effects:of</idno>
<idno type="wicri:Area/Main/Merge">007629</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10928571</idno>
<idno type="wicri:Area/PubMed/Corpus">003F54</idno>
<idno type="wicri:Area/PubMed/Curation">003F54</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004017</idno>
<idno type="wicri:Area/Ncbi/Merge">000297</idno>
<idno type="wicri:Area/Ncbi/Curation">000297</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000297</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Kulisevsky J:chronic:effects:of</idno>
<idno type="wicri:Area/Main/Merge">007160</idno>
<idno type="wicri:Area/Main/Curation">004B08</idno>
<idno type="wicri:Area/Main/Exploration">004B08</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients</title>
<author><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Movement Disorders Unit, Department of Neurology, Pharmacological Research Area, Sant Pau Hospital, Autonomous University of Barcelona</wicri:regionArea>
<wicri:noRegion>Autonomous University of Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Garcia Nchez, Carmen" sort="Garcia Nchez, Carmen" uniqKey="Garcia Nchez C" first="Carmen" last="García-Sánchez">Carmen García-Sánchez</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Movement Disorders Unit, Department of Neurology, Pharmacological Research Area, Sant Pau Hospital, Autonomous University of Barcelona</wicri:regionArea>
<wicri:noRegion>Autonomous University of Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Berthier, Marcelo L" sort="Berthier, Marcelo L" uniqKey="Berthier M" first="Marcelo L." last="Berthier">Marcelo L. Berthier</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Behavioural Neurology Unit, Clinic University Hospital and University of Málaga</wicri:regionArea>
<wicri:noRegion>Clinic University Hospital and University of Málaga</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barbanoj, Manel" sort="Barbanoj, Manel" uniqKey="Barbanoj M" first="Manel" last="Barbanoj">Manel Barbanoj</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Movement Disorders Unit, Department of Clinical Pharmacology Unit, Pharmacological Research Area, Sant Pau Hospital, Autonomous University of Barcelona</wicri:regionArea>
<wicri:noRegion>Autonomous University of Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pascual Edano, Berta" sort="Pascual Edano, Berta" uniqKey="Pascual Edano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Movement Disorders Unit, Department of Neurology, Pharmacological Research Area, Sant Pau Hospital, Autonomous University of Barcelona</wicri:regionArea>
<wicri:noRegion>Autonomous University of Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Movement Disorders Unit, Department of Neurology, Pharmacological Research Area, Sant Pau Hospital, Autonomous University of Barcelona</wicri:regionArea>
<wicri:noRegion>Autonomous University of Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Estevez Onzalez, Armando" sort="Estevez Onzalez, Armando" uniqKey="Estevez Onzalez A" first="Armando" last="Estévez-González">Armando Estévez-González</name>
<affiliation wicri:level="1"><country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Psychiatry and Clinical Psychology, University of Barcelona</wicri:regionArea>
<wicri:noRegion>University of Barcelona</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-07">2000-07</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="613">613</biblScope>
<biblScope unit="page" to="626">626</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">DC8FA77A0EBB7396A67D49664331B342CAE3AE5F</idno>
<idno type="DOI">10.1002/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F</idno>
<idno type="ArticleID">MDS1005</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Cognition</term>
<term>Cognition Disorders (diagnosis)</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognitive disorder</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Drug Therapy, Combination</term>
<term>Ergot derivatives</term>
<term>Female</term>
<term>Follow up study</term>
<term>Follow-Up Studies</term>
<term>Frontal Lobe (drug effects)</term>
<term>Frontal functions</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Skills (drug effects)</term>
<term>Neuropsychological Tests</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pergolide</term>
<term>Pergolide (adverse effects)</term>
<term>Pergolide (therapeutic use)</term>
<term>Treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
<term>Pergolide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
<term>Pergolide</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Frontal Lobe</term>
<term>Motor Skills</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cognition Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Ergot dérivé</term>
<term>Etude longitudinale</term>
<term>Homme</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Pergolide</term>
<term>Traitement</term>
<term>Trouble cognition</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND: The cognitive effects of dopaminergic treatment in Parkinson's disease (PD) are still controversial. OBJECTIVE: To evaluate, in previously untreated patients with PD, whether chronic dopaminergic stimulation produces significant cognitive changes; whether they are sustained beyond the period of a few months; and whether the cognitive status of two motor‐comparable groups is differently affected by levodopa and pergolide. DESIGN AND SUBJECTS: Parallel, randomized open study with blind neuropsychologic evaluation of 20 consecutive de novo patients with PD before and 3, 6, 12, 18, and 24 months after monotherapy with levodopa (n = 10) or pergolide (n = 10; 6‐month monotherapy; pergolide + levodopa thereafter). RESULTS: Both treatments were associated with a significant improvement in motor scores and in tests assessing learning and long‐term verbal and visual memory, visuospatial abilities, and various frontal tasks. While improvement in motor scores persisted, improvement in activities of daily living and in semantic fluency, Luria's rhythm and motor and long‐term memory tests was not sustained at the 24‐month examination. Further, performance on attentional, short‐term memory, and the Stroop tests did not change over the course of the study. CONCLUSIONS: Both treatments were associated with incomplete but long‐lasting (18 mos) improvement in many cognitive tasks which declined thereafter, suggesting that dopaminergic replacement is not enough to compensate for all cognitive deficits of PD.</div>
</front>
</TEI>
<affiliations><list><country><li>Espagne</li>
</country>
</list>
<tree><country name="Espagne"><noRegion><name sortKey="Kulisevsky, Jaime" sort="Kulisevsky, Jaime" uniqKey="Kulisevsky J" first="Jaime" last="Kulisevsky">Jaime Kulisevsky</name>
</noRegion>
<name sortKey="Barbanoj, Manel" sort="Barbanoj, Manel" uniqKey="Barbanoj M" first="Manel" last="Barbanoj">Manel Barbanoj</name>
<name sortKey="Berthier, Marcelo L" sort="Berthier, Marcelo L" uniqKey="Berthier M" first="Marcelo L." last="Berthier">Marcelo L. Berthier</name>
<name sortKey="Estevez Onzalez, Armando" sort="Estevez Onzalez, Armando" uniqKey="Estevez Onzalez A" first="Armando" last="Estévez-González">Armando Estévez-González</name>
<name sortKey="Garcia Nchez, Carmen" sort="Garcia Nchez, Carmen" uniqKey="Garcia Nchez C" first="Carmen" last="García-Sánchez">Carmen García-Sánchez</name>
<name sortKey="Gironell, Alexandre" sort="Gironell, Alexandre" uniqKey="Gironell A" first="Alexandre" last="Gironell">Alexandre Gironell</name>
<name sortKey="Pascual Edano, Berta" sort="Pascual Edano, Berta" uniqKey="Pascual Edano B" first="Berta" last="Pascual-Sedano">Berta Pascual-Sedano</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B08 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004B08 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:DC8FA77A0EBB7396A67D49664331B342CAE3AE5F
   |texte=   Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: A two‐year follow‐up study of previously untreated patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.